Arsenal Bridge Venture

Emerging manager

Built from this firm's Form D filings. The firm files no SEC adviser report.

Website: https://arsenalbridge.com
HQ: TX

Arsenal Bridge Venture advances biotechnology innovations from mid-continent research universities where commercial and venture networks are underdeveloped. Founding partners include Isaac Barchas and Jim Graham. The firm's portfolio companies named in the facts include Tetricus, Eradivir, MorphImmune, Novosteo, and Courage Therapeutics.

01 · Says / Does

Tag	Says	Does
Stages	Not stated	Not enough dated deals
Sectors	Biotech	Not enough dated deals
Regions	Not stated	Not enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

Fund	Year	Size	Status
Arsenal Bridge Venture III, LP Arsenal Bridge Ventures advances elite biotechnology innovations from mid-continent research universities where commercial and venture networks are underdeveloped. The firm sources deals through relationships with innovators and builds companies through leadership recruitment, capital deployment, and syndication. Inferred from the firm's website	approx. 2025	$7M (Form D)	Raising

03 · People across funds

Isaac Barchas, Founding Partner
Arsenal Bridge Venture III, LP (Named on Form D)
Jim Graham, Founding Partner
Arsenal Bridge Venture III, LP (Named on Form D)
Clay B. Siegall, PhD, Special Partner
Arsenal Bridge Venture III, LP (Team)
Jim Weiss, Partner
Arsenal Bridge Venture III, LP (Team)

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026